Skip to main content

Table 3 Changes in sitting systolic blood pressure, sitting diastolic blood pressure and low-density lipoprotein cholesterol at Week 8 from baseline

From: The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

  Treatment groups FMS/RSV vs. FMS FMS/RSV vs. RSV
  FMS/RSV
(N = 46)
FMS
(N = 45)
RSV
(N = 44)
LSM difference
(SE)
P-value LSM difference (SE) P-value
siSBP        
  Baseline 152.52 (9.85) 151.33 (8.99) 154.72 (9.46)     
  Week 8 132.05 (17.45) 134.63 (18.70) 150.21 (17.19)     
  Change −20.47 (15.60) −16.70 (16.54) −4.50 (15.50)     
   P-value <0.001a <0.001b 0.061a     
 ANCOVA results        
  LSM (SE) −21.89 (2.44) −19.61 (2.66) −6.86 (2.71) −2.28 (3.37)   −15.03 (3.39)  
  (95% C.I.) (−26.71, −17.07) (−24.88, −14.35) (−12.22, −1.50) (−8.94, 4.39) 0.500d (−21.75, −8.31) <0.001d
siDBP        
  Baseline 89.42 (8.32) 85.78 (9.30) 93.08 (8.46)     
  Week 8 80.10 (10.47) 79.58 (8.47) 91.73 (11.46)     
  Change −9.32 (11.23) −6.20 (9.98) −1.35 (9.18)     
   P-value <0.001a 0.001a 0.335a     
 ANCOVA results        
  LSM (SE) −10.13 (1.42) −9.45 (1.59) −1.18 (1.61) −0.68 (1.98)   −8.95 (2.02)  
  (95% C.I.) (−12.94, −7.31) (−12.60, −6.30) (−4.37, 2.01) (−4.60, 3.25) 0.734d (−12.94, −4.95) <0.001d
LDL-C        
  Baseline 171.33 (36.02) 164.09 (39.56) 161.39 (26.71)     
  Week 8 81.46 (27.10) 154.40 (52.37) 77.25 (23.33)     
  Percentage change −52.36 (12.97) −6.52 (20.48) −51.52 (15.80)     
   P-value <0.001b 0.112c <0.001c     
 ANCOVA results        
 LSM (SE) −52.74 (2.57) −5.83 (2.77) −50.92 (2.83) −46.91 (3.53)   −1.82 (3.57)  
 (95% C.I.) (−57.82, −47.66) (−11.31, −0.35) (−56.52, −45.31) (−53.89, −39.92) <0.001d (−8.89, 5.24) 0.611d
  1. FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, LDL-C low-density lipoprotein, siSBP sitting systolic blood pressure, siDBP sitting diastolic blood pressure, SD standard deviation, LSM least square mean, SE standard error, ANCOVA analysis of covariance
  2. Percent change from baseline was compared by apaired t-test, bone sample t-test, or cWilcoxon signed rank test
  3. dComparison between the combination therapy and monotherapy was analyzed by ANCOVA model adjusted for baseline values, age, gender and smoking status